Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design

V2, Crosslink

🧫

Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-chaperon

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design ## Background and Rationale Chaperone-mediated autophagy (CMA) is a selective degradation pathway that maintains cellular proteostasis by targeting specific proteins containing KFERQ-like motifs to lysosomes via the LAMP2A receptor and HSC70 chaperone complex. Recent evidence suggests CMA dysfunction may be an upstream pathogenic mechanism in Parkinson's Disease (PD), contributing to alpha-synuclein accumulation and neurodegene

METHODOLOGY NOTES

Phase 1 (Months 1-12): Patient-derived iPSC generation and characterization. Collect skin biopsies from 30 PD patients (early-stage, H&Y 1-2) and 20 age-matched controls. Reprogram to iPSCs using Sendai virus vectors, validate pluripotency markers, and differentiate into midbrain dopaminergic neurons using established protocols with SHH, FGF8, and BDNF. Phase 2 (Months 6-18): CMA pathway analysis in iPSC-derived neurons. Assess LAMP2A protein levels by Western blot and immunofluorescence, measure HSC70 expression, quantify CMA substrate degradation using fluorescent reporters, and analyze alpha-synuclein accumulation by ELISA and proximity ligation assay. Treat with CMA modulators (retinoic acid activation, 6-aminonicotinamide inhibition). Phase 3 (Months 12-24): Clinical biomarker validation. Recruit 100 PD patients and 50 controls for CSF and plasma collection. Measure LAMP2A, HSC70, and CMA substrates by ELISA, quantify alpha-synuclein species by RT-QuIC, assess lysosomal enzymes (c

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.898166Z'}
summary	# Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design ## Background and Rationale Chaperone-mediated autophagy (CMA) is a selective degradation pathway that maintains cellular proteosta
entities	{'genes': ['CMA'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Validate Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design
methodology_notes	Phase 1 (Months 1-12): Patient-derived iPSC generation and characterization. Collect skin biopsies from 30 PD patients (early-stage, H&Y 1-2) and 20 age-matched controls. Reprogram to iPSCs using Send
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.898171', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

679

Outgoing

635

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design

derives from (16)

supports (35)

💬 Discussion